Live virus vaccines are a critical component of worldwide vaccination strategy for reducing disease burden but often require complex biological production processes that are sensitive to many different factors, both known and often unknown. Prior application of high-throughput process development (HTPD) approaches to these processes has been hampered by a complex design space, low-throughput analytics, and challenges inherent in biosafety level 2 containment and asepsis in laboratory automation. In 2013, we initiated a project with HighRes Biosolutions to design and install an integrated high-throughput screening platform to enable HTPD for biosafety level 2 upstream process development studies. The system incorporates the necessary tools for performing cell and virus culture studies in microplates, as well as advanced analytical capabilities necessary for assessment of cell phenotype, product quality, and antigen yield. To date, we have applied this system to screen optimal media formulations and viral production conditions in support of two viral vaccine programs, with phenotypic assays performed as an integrated part of the workflow. This case study illustrates the power of HTPD in addressing large-scale biological screening challenges by narrowing a vast design space and identifying parameter interactions in live virus production processes.
Platform processes often used for the production of monoclonal antibodies can be credited with the industrialization of these microscale technologies, allowing broad applicability and consistent workflows across a growing market. However, vaccine development often employs non-platform processes using unique cell lines or expression systems, and the applicability of HTPD solutions remains challenging and requires flexible automation solutions.
Upstream bioprocesses for vaccines, specifically live and inactivated viruses, differ considerably from other therapeutic protein production processes. Viral vaccines are often produced in anchorage-dependent cell lines that lack the thorough characterization of Chinese hamster ovary cell lines used for most biopharmaceuticals [12, 13] . Multifactorial parameter interactions throughout each manufacturing process are often difficult to profile using conventional lab-scale experiments, due to limited throughput and the lengthy time cycles of production for some viruses. Further, many live virus production processes are subject to higher levels of biosafety handling procedures that require more intensive decontamination, isolation, and waste handling protocols, complicating the application of lab automation devices, such as liquid handling systems [14, 15] . Finally, product quality assessment for live viruses often requires panels of multiple assays, such as plaque potency and ELISA [16] that are generally difficult to apply to high-throughput studies with large numbers of samples.
Despite these challenges, application of HTPD approaches to viral vaccine production remains compelling, given the number of fundamental process parameters that are amenable to optimization in microplate static culture models. Examples of such parameters include cell substrate selection, culture age for infection, multiplicity of infection, and media development [12, 13] . Our group envisioned a new paradigm for live virus vaccine process development utilizing HTPD to profile multifactorial parameter interactions and evaluate process design options prior to scale-up. Culture media development represents a primary focus in this approach. Vaccine cell culture media often contain fetal bovine serum (FBS), which exhibits lot-to-lot variability and comprises the majority of raw material costs [17] . Media development can simultaneously strive to reduce or eliminate dependence on FBS while seeking conditions that provide increased viral productivity [18] . Microplate-based experimental models can rapidly identify potential media additives via singleconcentration screens for the greatest throughput, or doseresponse format to evaluate minimum effective concentration and toxicity limits. The large variety of culture media additives available and the potential for interactions among them illustrates the vastness of the design space to be navigated in the design of such processes. While there are multiple reports in the literature about the development of defined media for Chinese hamster ovary cell growth [17] [18] [19] [20] [21] [22] , there is insufficient literature describing the use of HTPD for viral vaccine culture media development.
The magnitude of this screening problem may be likened to that faced by drug discovery high-throughput screening (HTS) groups, who routinely screen very large compound collections for therapeutic targets. We therefore approached cell culture development in a similar manner, using similar automation tools and employing a "funnel" methodology to identify lead candidates [23] . Primary screens are thought of as the widest point of the funnel (Fig. 1 ), designed to rapidly identify areas of interest within the design space (or, by analogy, compound collection) for further counter-screening and follow-up. As leads are identified, they progress to narrower sections of the funnel where they can be validated using lab-scale cell culture models. There are numerous reports in the literature of successful small-molecule HTS campaigns using viral infectivity for primary screening [24] [25] [26] [27] [28] , although in many of these studies the objective was to inhibit viral infection rather than optimize it. In this report, we describe both the design and creation of an integrated robotic system for vaccine cell culture HTPD and selected applications of the automation system to media development for a viral vaccine currently in development. The miniaturization and automation of media development workflows have allowed the scale of experimentation to increase by orders of magnitude, increasing our insight into the biology of cell growth and virus production and thereby improving process performance. 
Materials and methods

Automation system design
The automation system was designed in partnership with High-Res Biosolutions (Woburn, MA, USA) to accommodate diverse workflows involving cell and virus cultures performed in tissue culture (TC) microplates. A system schematic showing the layout of devices is shown in Fig. 2A . The core of the automation system is a 5-axis robotic arm on a 1.5 m motion rail (HighRes Biosolutions A-Cell), which traverses the length of the system to move plates through the system as needed. All instruments are controlled by central director software (HighRes Biosolutions Cellario TM ), which handles workflow execution and scheduling. Biocontainment is provided by a hard-walled, high-efficiency particulate arresting (HEPA)-filtered, full-system enclosure that maintains a negative internal pressure to the surrounding lab space (HighRes Biosolutions). A labware carousel serves as the primary input/output location for labware (HighRes Biosolutions Ambistore). A Hamilton STAR Plus liquid handling robot (Hamilton Robotics, Reno, NV, USA) equipped with a laminar flow HEPA canopy is included for the aseptic creation, sampling, and manipulation of such plates. Three incubators are located within the system (Liconic STX, Woburn, MA, USA), with units dedicated to refrigerated storage and cell culture incubation. Inclusion of multiple incubators allows temperature to be studied as an HTPD variable. Two combination plate washer and reagent dispenser instruments are included (Biotek EL406, Winooski, VT, USA), for washing of cell monolayers during analytical methods. A centrifuge within the system (HighRes Biosolutions MicroSpin) allows the washing of cells in suspension if desired. Two additional reagent-dispensing instruments (Biotek Multiflo TM and Formulatrix Tempest, Bedford, MA, USA) are included for miscellaneous reagent addition steps. Three different analytical devices are integrated in the system, including a multimode plate reader (Biotek SynergyH4 TM ), a high-content imager (Biotek Cytation TM ), and an HTS flow cytometer (Intellicyt iQue R Screener, Albuquerque, NM, USA).
Figure 2. (A)
HighRes system overview. Devices are arranged on either side of the motion rail for the robotic arm. In many areas of the system, devices are arranged in multiple layers for optimal space utilization. The entire system is enclosed in a biocontainment enclosure that is HEPA filtered (not shown). (B) Workflow summary for media development for both cell growth and viral infection. Different media combinations are first prepared in microplates and subsequently planted with the cell line under study. These plates are then stamped to create time point copies in fresh plates. At appropriate times following cell plant, some of these plates are media exchanged and infected with virus. Each time point plate is fixed at desired times using formaldehyde fixation, then assayed by primary high-content imaging assays to identify conditions of interest. If desired, samples can be cherry-picked from supernatant retain plates for secondary assays to verify leads.
Virus and cell culture
A proprietary human epithelial cell line was routinely cultured in DMEM/F12 culture media containing 10% FBS (Life Technologies, Grand Island, NY, USA). Cells were maintained in TC flasks (Corning Life Sciences, Corning, NY, USA) at 37°C with 5% CO 2 during culture. At desired times, cells were harvested using TrypLE TM (Life Technologies) and quenched using the growth media described above. Harvested cells were counted and assayed for viability using a ViCell R instrument (Beckman Coulter, Danvers, MA, USA) and used immediately in automated screening studies.
Working virus stock for the viral vaccine in this study was stored under liquid nitrogen prior to use, in DMEM/F12 media with 10% FBS supplemented with sucrose for cryopreservation. A viral potency for the stock is used for all infection calculations based on prior characterization using a plaque potency assay. Infection of cells is accomplished by media exchange into an infection medium containing the virus stock at an appropriate multiplicity of infection.
Media preparation
Media supplement libraries were prepared from stock solutions of selected components dissolved in DMEM/F12 media (Life Technologies). Solutions were blended using a Hamilton STAR liquid handler system equipped with a HEPA laminar flow canopy (Hamilton Robotics). A customized workbook was created in Microsoft Excel to translate specified media recipes to pipetting instructions that are then executed by the Hamilton STAR. Media were prepared in sterile 24-well blocks (Corning Life Sciences) and used immediately following preparation.
Automated media screening
A summary of the screening workflow is shown in Fig. 2B . Human epithelial cells were plated at a density of 1 × 10 4 viable cells per square centimeter in black-wall, clear-bottom, 96-well TC plates (Corning Life Sciences). For growth studies, plates were incubated at 37°C with 5% CO 2 for the desired time period prior to sampling or viral infection. For viral infection media screening studies, seeded plates at or near confluence were removed from incubation and growth media was aspirated from wells using the Hamilton STAR Plus liquid handler. Infection media containing virus at the desired concentration was then added to wells by the liquid handler and plates were subsequently returned to incubation at 37°C with 5% CO 2 for infection to proceed. Plates were sacrificed at regular intervals to track growth and viral spread kinetics. At time of sacrifice, plates were removed from incubation and washed with PBS containing 0.1% Tween-20 (Teknova, Hollister, CA, USA) using a plate washer in the automation system. Wash buffer was aspirated and 100 uL of 2% formaldehyde (Sigma, St. Louis, MO, USA) in PBS was added to wells to fix cells. Plates were incubated for 30 min at room temperature, and then washed twice with PBS containing 0.1% Tween-20 (PBST). Fixed plates were stored at 4°C prior to high-content imaging assay.
Cytotoxicity and functional testing of cell culture media components
Human epithelial cells were plated at a density of 1 × 10 4 viable cells per square centimeter in blank, clear-bottom, 96-well TC plates, as described above. For growth studies, plates were seeded and then incubated at 37°C with 5% CO 2 overnight to allow cell attachment to the well surface. For viral infection media screening studies, seeded plates were incubated under similar conditions until they reached 90-100% confluency. Cytotoxicity studies were initiated by aspirating growth media from wells using the Hamilton STAR Plus liquid handler and replacing it with an equal volume of media containing serial dilutions of the desired components in DMEM/F12 media containing either 10% (for growth) or 1% (for infection) FBS (Gibco). Plates were then returned to incubation at 37°C with 5% CO 2 . Plates were sacrificed at regular intervals in a similar manner as described above.
High content imaging assays for cell growth and viral spread
Fixed plates were retrieved from 4°C storage and washed in between subsequent staining steps with PBST using a plate washer.
Plates were permeabilized with 0.1% Triton X-100 in PBS and blocked with 1% BSA in PBS. After washing twice in PBST, cells were incubated with an in-house developed primary antibody recognizing a nuclear viral protein and visualized with an anti-species secondary antibody labeled with AlexaFluor488 (Life Technologies). Additionally, cell nuclei were stained with Hoechst 33342 (Life Technologies). Following the completion of staining, plates were stored in diminished light until imaging. Plates were imaged for Hoechst 33342 and AlexaFluor488 fluorescence using a Cytation3 TM high-content imaging system (Biotek). Cell growth data was determined based on nuclei counts and infected cells were identified by co-localization of AlexaFluor488 and Hoechst 33342 objects.
Results and discussion
System design
In this work, we created an integrated robotic system that allows full walk-away automation of both cell culture process development and analytical workflows, simultaneously. The system is equipped with many common devices that are applied to increase throughput of cell-based assays within HTS groups, such as microplate reagent dispensers and plate washers. However, in contrast to many integrated robotic systems, our system was not designed to maximize efficiency of a specific workflow. Instead, a "Swiss army knife" approach provides a variety of devices capable of executing a diverse set of workflows, providing maximal flexibility for present and future needs alike. Many of the assay methods used for characterization of vaccines are complex and not amenable to HTS, but may represent the most appropriate assessment of product quality for HTPD screening. By providing the necessary tools to perform diverse methods such as high-content imaging, immunoassays, and flow cytometry within the robotic system, we are able to execute one or more primary assays on samples from large HTPD screens to identify factors that are worthy of further study, without overwhelming existing low-throughput assays. Biocontainment and sterility characterization of the High-Res system have been performed using airflow profiling, airborne particle counting, and media challenge studies (data not shown). An air-driven liquid handler was specifically selected for this system to control contamination risk that can be inherent in instruments that use a system liquid to drive pipetting. The full-system HEPA enclosure maintains a negative-pressure environment such that viruses or cell lines that are biosafety level 2 can be screened with assured containment of aerosols originating from devices or pipetting, as well as increased operator safety. We have opted to provide an additional level of aseptic protection by incorporating the laminar flow HEPA canopy on the Hamilton liquid handler, which is fully enclosed within the system enclosure, thus providing biocontainment and asepsis simultaneously. Multiple media challenge studies using rich growth media have shown that routine liquid handling operations on the Hamilton STAR Plus system can be performed aseptically, without the need for antibiotics in cell cultures.
Historically, plate-based experiments were performed by hand, resulting in a tremendous burden of tedious, manual effort and limited throughput. Miniaturization of process development studies to 96-well microplate format offers numerous advantages, including an increase in experimental replicates, number of experimental conditions that can be executed, and a reduction in the reagents needed. Further automation of these studies using common lab automation devices has resulted in a considerable reduction in manual workload, as well as increased accuracy and reproducibility. Indeed, the introduction of the HighRes system has allowed a 5-to 10-fold increase in throughput, compared to manual methods, with less hands-on time needed. We have leveraged this increased throughput to increase statistical rigor via replication to profile process variability, and also to screen a larger number of process conditions per study. Increased replication is particularly powerful for vaccine production in diverse cell lines, where the innate variability in viral biology can be difficult to characterize using time-intensive labscale processes. Likewise, the use of HTPD automation can allow adequate exploration of the vast design space and discovery of interactions between process variables and factors. In 2014, the HighRes automation system performed over 35 000 wells of cell culture studies for one of our current vaccine development programs, supported by a single scientist. Experimentation of this scale would not be possible manually, given that it would take an impractically long time to complete. Thus, automation allows a simultaneous increase in both the statistical replication and number of experiments performed.
Automated media component screening
The power of upstream HTPD can be fully leveraged for the screening of cell culture media component screening and toxicity testing. Media development involves screening libraries of supplements to identify components that can either be added to basal media to enhance productivity of virus culture, reduce the level of serum needed [18] , or both goals simultaneously. These goals are easily extended to the search for serum-free media formulations [20, 21] , which would be a significant benefit to process economics and reliability of vaccine supply. Historically, media component screening has generally been performed in labor-intensive lab-scale cell culture formats, such as TC flasks or roller bottles, leading to limitations in the number of experimental conditions that can be performed by a single scientist. These studies grow rapidly in size when replicate samples are added, when kinetic time course data is desired for cell growth or virus infection, or when full-factorial studies are needed. By transitioning these studies to microplates and using lab automation systems to manage time point plate assays and sampling, media component screens can be exponentially expanded in size and complexity. The richness of the resulting data set can allow a more complete view of the media component design space and identification of interactions between individual supplements being screened. We have focused on the gathering of kinetic data for measuring viral spread as a primary assay for screening media components, rather than an endpoint read of viral abundance at a single time point. However, a number of different assay formats can be utilized to evaluate viral potency and culture productivity using the tools in the automation system described here.
Media component libraries contained several classes of media supplements, such as various basal media, growth factors, hormones, alternate serum types, fatty acids, and amino acids. Miniaturization of screening studies to microwell plates allows very large multifactorial studies to be completed efficiently, increasing the richness of data and the number of components that can be screened. The general workflow for screening is shown in Fig. 2B . In one example study evaluating serum-free media alternatives for cell growth and viral infection, 60 unique media formulations were tested in microplate format. Cell plates were fixed using formaldehyde at regular intervals, yielding data on cell growth and virus infection kinetics. Results for this particular study revealed a wide spectrum of different cellular responses to the supplements evaluated, ranging from extremely poor performance to nearly equivalent to cultures containing control concentrations of FBS (Figs. 3A and B ). Using this data, specific classes of additives can be identified for their efficacy and further explored for their potential to contribute to a serum-free media formulation. This approach enables a rapid identification of media formulation "leads" that can be brought forward for testing in larger-scale formats, without the burden of doing the original screening studies in those formats. The microplate format for this study resulted in nearly a 250-fold scale-down from T-75 TC flasks. Additionally, the use of automated systems for plate setup, sampling, and analysis in this study avoided the need to run 60 media formulations in T-75 flasks with replication, representing a significant resource savings.
Toxicity screening workflow
Cell culture supplement screening requires data on the useful range of concentrations that can be added to the culture, including the upper limit that defines toxicity. Media components that may show a benefit to cell growth rates may be deleterious to viral production, as our group has observed in several component screens. Production of the herpes virus described in the case studies presented herein requires the use of FBS. FBS contributes a diverse set of critical molecular raw materials to both cellular metabolism and viral particle assembly. However, the use of greater concentrations of FBS may not necessarily lead to improved culture productivity and several literature reports on the toxicity of FBS to viral production have been noted [29] [30] [31] . As such, it is imperative to develop a thorough understanding of FBS concentration as it pertains to the overall health of the culture, as well as viral productivity. Automated toxicity screens were performed for multiple lots of FBS using a dose-response format and direct measures of process performance, such as cell growth rates and viral productivity were measured. Optimal cell growth was observed at 10% v/v FBS in the growth media (data not shown). However, during viral infection of cells, a production. Four different lots were screened for potential differences in viral potency and resulting data showed inhibition of viral potency at concentrations exceeding ß2%, as well as lot-to-lot differences in viral potency at sub-inhibitory concentrations.
dose-dependent toxicity of FBS was observed beginning at 2-3% v/v. This effect was observed reproducibly for four different lots of FBS (Fig. 3C) . Additionally, viral potency maintained a plateau value below this toxicity limit and this plateau appeared to be different across FBS lots, suggesting that some lots have a higher capacity to produce high-potency virus than others. These findings have led to a greater investigation of FBS source and lotto-lot performance. Additionally, this applied-use screening approach for media component toxicity provides a greater level of understanding for process impact than traditional HTS cytotoxicity assay formats, such as lactate dehydrogenase measurements in culture supernatant.
Concluding remarks
The automation system described here has been successfully applied for a wide variety of studies since it was commissioned in early 2014. The use of an integrated robotic system, while ini-tially viewed by some as unnecessarily complex, allows complete HTPD workflows to be fully automated with relative ease. The two core workflows described in this paper for media and toxicity screening are now in production for multiple vaccine programs ranging from discovery to later phases of development. The advent of integrated automation systems for viral vaccine HTPD studies has allowed our group to reconsider large-scale biological profiling studies, such as screening supplements to affect specific molecular pathways for the purpose of improving productivity or mitigating specific cellular stress pathways. These screening studies can be carried out with a variety of different phenotypic or potency-based assay methods, using the diverse analytical tools available on the HighRes screening system. Furthermore, the ability to run large-scale cell growth and infection studies has led to a greater capability for cellular engineering, including the selection and refinement of high-producing cell clones based on either applied-use testing or phenotypespecific assays, or both. The overall impact of this system will ultimately lead to better understanding, faster development, and www.els-journal.com Eng. Life Sci. 2016, 16, [202] [203] [204] [205] [206] [207] [208] [209] www.biotecvisions.com improved characterization for vaccine production processes in the future.
Practical application
This report details the design of an integrated robotic automation system for high-throughput screening studies in support of viral vaccine process development under biosafety level 2 conditions. Specific examples are described for culture media development, including automated screening of component libraries to optimize viral productivity and serum utilization. The system described in this report has broad applicability to many different process development initiatives supporting viral vaccine development, including optimization of viral infection conditions and harvest times. Additionally, the system is designed with a diverse set of analytical instruments capable of executing multiple analytical assays in parallel with process development, decreasing the time needed for large screens to be completed. Implementation of the system has greatly increased the scope of experimentation that is routinely performed and the richness of the resulting screening data, without adding a prohibitive level of complexity.
